These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 6273562)

  • 21. [A simple method of synthesis of S-sulfoxides of penicillanic acid and 6-alpha-bromo[chloro]-penicillanic acids].
    Changov LS; Vasileva-Lukanova BK; Agapova NN; Tsenkova MM; Mondeshka DM; Ivanova ZT
    Antibiot Khimioter; 1990 Aug; 35(8):12-3. PubMed ID: 2176073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selection of variants of the TEM-1 beta-lactamase, encoded by a plasmid of clinical origin, with increased resistance to beta-lactamase inhibitors.
    Thomson CJ; Amyes SG
    J Antimicrob Chemother; 1993 May; 31(5):655-64. PubMed ID: 8392995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Beta-lactamase inhibition by acetylmethylene penicillanic acid compared to that of clavulanate and sulbactam.
    Chin NX; McElrath MJ; Neu HC
    Chemotherapy; 1988; 34(4):318-25. PubMed ID: 2850139
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inactivation of the thiol RTEM-1 beta-lactamase by 6-beta-bromopenicillanic acid. Identity of the primary active-site nucleophile.
    Knap AK; Pratt RF
    Biochem J; 1987 Oct; 247(1):29-33. PubMed ID: 2825657
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activity of 13 beta-lactam agents combined with BRL 42715 against beta-lactamase producing gram-negative bacteria compared to combinations with clavulanic acid, tazobactam and sulbactam.
    Piddock LJ; Jin YF; Turner HL
    J Antimicrob Chemother; 1993 Jan; 31(1):89-103. PubMed ID: 8383105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tazobactam is a potent inactivator of selected inhibitor-resistant class A beta-lactamases.
    Bonomo RA; Rudin SA; Shlaes DM
    FEMS Microbiol Lett; 1997 Mar; 148(1):59-62. PubMed ID: 9066111
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structural Variabilities in β-Lactamase (blaA) of Different Biovars of Yersinia enterocolitica: Implications for β-Lactam Antibiotic and β-Lactamase Inhibitor Susceptibilities.
    Singhal N; Srivastava A; Kumar M; Virdi JS
    PLoS One; 2014; 10(4):e0123564. PubMed ID: 25919756
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Susceptibility of Escherichia coli isolates with TEM-1 beta-lactamase to combinations of BRL42715, tazobactam or clavulanate with piperacillin or amoxycillin .
    Livermore DM; Seetulsingh P
    J Antimicrob Chemother; 1991 Jun; 27(6):761-7. PubMed ID: 1669013
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic activity of cefoperazone in combination with beta-lactamase inhibitors.
    Fu KP; Neu HC
    J Antimicrob Chemother; 1981 Mar; 7(3):287-92. PubMed ID: 6268598
    [No Abstract]   [Full Text] [Related]  

  • 30. In-vitro susceptibility of the Bacteroides fragilis group to cefoperazone, ampicillin, ticarcillin and amoxycillin combined with beta-lactamase inhibitors.
    Barry AL; Jones RN; Packer RR
    J Antimicrob Chemother; 1986 Jan; 17(1):125-7. PubMed ID: 3005222
    [No Abstract]   [Full Text] [Related]  

  • 31. Design, synthesis, and biological evaluation of a series of beta-lactam-based prodrugs.
    Hakimelahi GH; Shia KS; Xue C; Hakimelahi S; Moosavi-Movahedi AA; Saboury AA; Khalafi-Nezhad A; Soltani-Rad MN; Osyetrov V; Wang K; Liao JH; Luo FT
    Bioorg Med Chem; 2002 Nov; 10(11):3489-98. PubMed ID: 12213463
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A semi-synthetic penicillinase inactivator.
    Cartwright SJ; Coulson AF
    Nature; 1979 Mar; 278(5702):360-1. PubMed ID: 218114
    [No Abstract]   [Full Text] [Related]  

  • 33. Synthesis and beta-lactamase inhibitory activity of 6-fluoropenicillanic acids.
    Danelon GO; Laborde M; Mascaretti OA; Boggio SB; Roveri OA
    Bioorg Med Chem; 1993 Dec; 1(6):447-55. PubMed ID: 8087566
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An in vitro evaluation of clavulanic acid, a potent, broad-spectrum beta-lactamase inhibitor.
    Greenwood D; O'Grady F; Baker P
    J Antimicrob Chemother; 1979 Sep; 5(5):539-47. PubMed ID: 387706
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and beta-lactamase inhibitory activity of new 6beta-cysteinesulfonamidopenicillanic acids.
    Changov LS; Naydenova ED; Ivanova GI; Gergova RT; Keuleyan EE; Aleksiev BV
    Bioorg Med Chem; 1999 Dec; 7(12):2899-904. PubMed ID: 10658594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibacterial activities of amoxicillin alone and in combination with clavulanic acid correlated with beta-lactamase production.
    Hsu LY; Chang SC; Luh KT; Hsieh WC
    Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1991 Aug; 24(3):272-80. PubMed ID: 1818798
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential prodrugs of 6-acetylmethylenepenicillanic acid (Ro 15-1903).
    Adam S; Then R; Angehrn P
    J Antibiot (Tokyo); 1986 Jun; 39(6):833-8. PubMed ID: 3015853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 'Beta-lactams' as beta-lactamase inhibitors.
    Cole M
    Philos Trans R Soc Lond B Biol Sci; 1980 May; 289(1036):207-23. PubMed ID: 6109317
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 6-beta-bromopenicillanic acid, a potent beta-lactamase inhibitor.
    Pratt RF; Loosemore MJ
    Proc Natl Acad Sci U S A; 1978 Sep; 75(9):4145-9. PubMed ID: 212736
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protection of piperacillin and ticarcillin from beta-lactamase hydrolysis by tazobactam (YTR-830) and clavulanic acid.
    Diver JM; Thornber D; Wise R
    J Antimicrob Chemother; 1989 Jul; 24(1):89-92. PubMed ID: 2550415
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.